Cancer stem cell-targeted therapeutic approaches for overcoming trastuzumab resistance in HER2-positive breast cancer
Y Qiu, L Yang, H Liu, X Luo - Stem Cells, 2021 - academic.oup.com
Application of the anti-HER2 drug trastuzumab has significantly improved the prognosis of
patients with the HER2-positive subtype of breast cancer. However, 50% of patients with …
patients with the HER2-positive subtype of breast cancer. However, 50% of patients with …
Cancer stem cell‐targeted therapeutic approaches for overcoming trastuzumab resistance in HER2‐positive breast cancer.
Y Qiu, L Yang, H Liu, X Luo - Stem Cells, 2021 - search.ebscohost.com
Application of the anti‐HER2 drug trastuzumab has significantly improved the prognosis of
patients with the HER2‐positive subtype of breast cancer. However, 50% of patients with …
patients with the HER2‐positive subtype of breast cancer. However, 50% of patients with …
Cancer stem cell-targeted therapeutic approaches for overcoming trastuzumab resistance in HER2-positive breast cancer.
Y Qiu, L Yang, H Liu, X Luo - Stem Cells (Dayton, Ohio), 2021 - europepmc.org
Application of the anti-HER2 drug trastuzumab has significantly improved the prognosis of
patients with the HER2-positive subtype of breast cancer. However, 50% of patients with …
patients with the HER2-positive subtype of breast cancer. However, 50% of patients with …
Cancer stem cell‐targeted therapeutic approaches for overcoming trastuzumab resistance in HER2‐positive breast cancer
Y Qiu, L Yang, H Liu, X Luo - STEM CELLS, 2021 - Wiley Online Library
Application of the anti‐HER2 drug trastuzumab has significantly improved the prognosis of
patients with the HER2‐positive subtype of breast cancer. However, 50% of patients with …
patients with the HER2‐positive subtype of breast cancer. However, 50% of patients with …
Cancer stem cell-targeted therapeutic approaches for overcoming trastuzumab resistance in HER2-positive breast cancer
Y Qiu, L Yang, H Liu, X Luo - Stem cells (Dayton, Ohio), 2021 - pubmed.ncbi.nlm.nih.gov
Application of the anti-HER2 drug trastuzumab has significantly improved the prognosis of
patients with the HER2-positive subtype of breast cancer. However, 50% of patients with …
patients with the HER2-positive subtype of breast cancer. However, 50% of patients with …